Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND-T2D-2: Retatrutide vs Semaglutide in Type 2 Diabetes
NCT06260722Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of retatrutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Feb 2024; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06260722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260722.